دورية أكاديمية
أعرض في EDS

The vagus nerve mediates the physiological but not pharmacological effects of PYY 3-36 on food intake.

التفاصيل البيبلوغرافية
العنوان: The vagus nerve mediates the physiological but not pharmacological effects of PYY 3-36 on food intake.
المؤلفون: Alonso AM; Section of Investigative Medicine and Endocrinology, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, United Kingdom., Cork SC; Section of Investigative Medicine and Endocrinology, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, United Kingdom; School of Medicine, Faculty of Health, Education, Medicine & Social Care, Anglia Ruskin University, Chelmsford, CM1 1SQ, United Kingdom., Phuah P; Section of Investigative Medicine and Endocrinology, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, United Kingdom., Hansen B; Department of Bioengineering, Imperial College London, London, United Kingdom., Norton M; Section of Investigative Medicine and Endocrinology, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, United Kingdom., Cheng S; Section of Investigative Medicine and Endocrinology, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, United Kingdom., Xu X; Department of Bioengineering, Imperial College London, London, United Kingdom., Suba K; Department of Bioengineering, Imperial College London, London, United Kingdom., Ma Y; Section of Investigative Medicine and Endocrinology, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, United Kingdom., Dowsett GK; Medical Research Council Metabolic Diseases Unit, Wellcome-MRC Institute of Metabolic Science, University of Cambridge, United Kingdom., Tadross JA; Medical Research Council Metabolic Diseases Unit, Wellcome-MRC Institute of Metabolic Science, University of Cambridge, United Kingdom., Lam BY; Medical Research Council Metabolic Diseases Unit, Wellcome-MRC Institute of Metabolic Science, University of Cambridge, United Kingdom., Yeo GS; Medical Research Council Metabolic Diseases Unit, Wellcome-MRC Institute of Metabolic Science, University of Cambridge, United Kingdom., Herzog H; Neuroscience Division, Garvan Institute of Medical Research, Darlinghurst, Australia., Bloom SR; Section of Investigative Medicine and Endocrinology, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, United Kingdom., Arnold M; Department of Health Sciences and Technology, ETH Zurich, Schwerzenbach, Switzerland., Distaso W; Imperial College Business School, Imperial College London, United Kingdom., Murphy KG; Section of Investigative Medicine and Endocrinology, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, United Kingdom., Salem V; Section of Investigative Medicine and Endocrinology, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, United Kingdom; Department of Bioengineering, Imperial College London, London, United Kingdom. Electronic address: v.salem@imperial.ac.uk.
المصدر: Molecular metabolism [Mol Metab] 2024 Mar; Vol. 81, pp. 101895. Date of Electronic Publication: 2024 Feb 08.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier GmbH Country of Publication: Germany NLM ID: 101605730 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2212-8778 (Electronic) Linking ISSN: 22128778 NLM ISO Abbreviation: Mol Metab Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [München] : Elsevier GmbH, 2012-
مواضيع طبية MeSH: Peptide YY*/physiology , Gastrointestinal Hormones*, Appetite/physiology ; Vagus Nerve ; Eating
مستخلص: Peptide YY (PYY 3-36 ) is a post-prandially released gut hormone with potent appetite-reducing activity, the mechanism of action of which is not fully understood. Unravelling how this system physiologically regulates food intake may help unlock its therapeutic potential, whilst minimising unwanted effects. Here we demonstrate that germline and post-natal targeted knockdown of the PYY 3-36 preferring receptor (neuropeptide Y (NPY) Y2 receptor (Y2R)) in the afferent vagus nerve is required for the appetite inhibitory effects of physiologically-released PYY 3-36 , but not peripherally administered pharmacological doses. Post-natal knockdown of the Y2R results in a transient body weight phenotype that is not evident in the germline model. Loss of vagal Y2R signalling also results in altered meal patterning associated with accelerated gastric emptying. These results are important for the design of PYY-based anti-obesity agents.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 The Authors. Published by Elsevier GmbH.. All rights reserved.)
معلومات مُعتمدة: MR/S026193/1 United Kingdom MRC_ Medical Research Council; MC_UU_00014/5 United Kingdom MRC_ Medical Research Council; MC_UU_12012/1 United Kingdom MRC_ Medical Research Council; MC_UU_00014/1 United Kingdom MRC_ Medical Research Council; MC_UU_12012/5 United Kingdom MRC_ Medical Research Council
فهرسة مساهمة: Keywords: Appetite; Gut hormones; PYY; Vagus nerve
المشرفين على المادة: 106388-42-5 (Peptide YY)
0 (Gastrointestinal Hormones)
تواريخ الأحداث: Date Created: 20240210 Date Completed: 20240308 Latest Revision: 20240313
رمز التحديث: 20240313
مُعرف محوري في PubMed: PMC10877939
DOI: 10.1016/j.molmet.2024.101895
PMID: 38340808
قاعدة البيانات: MEDLINE
الوصف
تدمد:2212-8778
DOI:10.1016/j.molmet.2024.101895